Representative Kim Schrier (D-WA) has been officially designated as the incoming Democratic co-chair of the Congressional Diabetes Caucus, a pivotal leadership role within one of the largest and most influential bicameral organizations in the United States Congress. Representative Schrier is slated to succeed Representative Diana DeGette (D-CO), who will conclude her tenure in the House of Representatives at the end of the current term. The leadership transition is scheduled to take place when the new Congress convenes in January 2027, following Representative DeGette’s re-election loss earlier this year. Representative Gus Bilirakis (R-FL) will remain in his position as the Republican co-chair, ensuring a level of bipartisan continuity for the caucus as it prepares to navigate a new legislative landscape.
The appointment of Representative Schrier marks a significant milestone for the caucus. She currently stands as the only pediatrician serving in Congress and holds the distinction of being the only representative living with type 1 diabetes. Diagnosed at the age of 16, Schrier’s personal and professional background provides her with a dual-perspective—both as a medical provider and a patient—that is expected to deeply inform the caucus’s legislative priorities. As the healthcare sector faces evolving challenges regarding drug pricing, insurance coverage, and research funding, Schrier’s elevation to co-chair signals a continued focus on evidence-based policy and patient-centered advocacy.
A Leadership Transition Grounded in Experience
The Congressional Diabetes Caucus has long been a bastion of bipartisan cooperation, focusing on the education of Members of Congress and their staff about the mechanics of diabetes and the legislative requirements to combat the epidemic. The departure of Representative Diana DeGette represents the end of an era for the caucus. DeGette has been a vocal proponent of diabetes research and was instrumental in the passage of the 21st Century Cures Act, as well as various initiatives aimed at capping the out-of-pocket costs of insulin.
Representative Schrier’s transition into this role is viewed by many in the medical community as a natural progression. Since entering Congress, Schrier has utilized her medical expertise to advocate for expanded healthcare access and lower prescription drug costs. Her firsthand experience managing type 1 diabetes for decades allows her to speak with unique authority on the daily burdens of the disease, from the rising costs of continuous glucose monitors (CGMs) to the life-or-death necessity of affordable insulin.
The partnership between Schrier and Representative Gus Bilirakis is expected to maintain the caucus’s tradition of reaching across the aisle. Bilirakis, who has served as the Republican co-chair, has a long history of working on rare disease legislation and healthcare accessibility. Together, the two leaders will oversee a caucus that comprises nearly 300 members of the House and Senate, making it one of the most robust advocacy groups within the federal government.
The Growing Economic and Public Health Burden of Diabetes
The urgency of the caucus’s work is underscored by the staggering statistics surrounding diabetes in the United States. According to the Centers for Disease Control and Prevention (CDC), more than 38 million Americans—roughly 11.6% of the population—have diabetes. Of those, approximately 5% to 10% have type 1 diabetes, an autoimmune condition where the body does not produce insulin. The remaining 90% to 95% suffer from type 2 diabetes, which is often linked to insulin resistance and can sometimes be managed or delayed through lifestyle interventions.
The economic impact is equally concerning. A 2022 study by the American Diabetes Association (ADA) estimated that the total annual cost of diagnosed diabetes in the U.S. was $412 billion. This includes $307 billion in direct medical costs and $105 billion in indirect costs, such as reduced productivity and disability. For many patients, the most visible portion of these costs is the price of insulin. While the Inflation Reduction Act of 2022 successfully capped insulin costs at $35 per month for seniors on Medicare, many individuals in the private insurance market or those without insurance still face high costs for the life-saving hormone.
Legislative Priorities: The Special Diabetes Program and Beyond
One of the primary responsibilities of the Congressional Diabetes Caucus is the oversight and reauthorization of the Special Diabetes Program (SDP). Established in 1997, the SDP consists of two components: the Special Statutory Funding Program for Type 1 Diabetes Research, administered by the National Institutes of Health (NIH), and the Special Diabetes Program for Indians (SDPI), administered by the Indian Health Service (IHS).
The SDP has been credited with several breakthroughs in diabetes technology, including the development of artificial pancreas systems and advancements in retinal imaging to prevent blindness. For indigenous communities, the SDPI has been vital in reducing the incidence of end-stage renal disease, a common and devastating complication of diabetes.
Representative Schrier has consistently advocated for long-term, multi-year funding for the SDP, rather than the short-term extensions that have characterized recent budget cycles. Medical organizations, including the Endocrine Society and the Juvenile Diabetes Research Foundation (JDRF), have emphasized that long-term funding is essential for the stability of clinical trials and the retention of top-tier researchers.
In addition to the SDP, the caucus under Schrier’s leadership is expected to focus on:
- Insulin Affordability: Expanding price protections to all Americans, regardless of insurance status.
- Technological Access: Ensuring that Medicare and private insurers cover the latest diabetes technologies, such as smart insulin pens and integrated CGM systems.
- Preventative Care: Enhancing funding for the National Diabetes Prevention Program (National DPP) to stem the tide of type 2 diabetes diagnoses.
- Research for a Cure: Increasing NIH funding for cellular therapies and immunotherapy that could potentially reverse type 1 diabetes.
Chronology of the Congressional Diabetes Caucus and Recent Milestones
To understand the context of Representative Schrier’s appointment, it is helpful to review the timeline of the caucus and recent legislative efforts:
- 1996: The Congressional Diabetes Caucus is formed to provide a forum for members to learn about the disease and coordinate legislative efforts.
- 1997: The Special Diabetes Program (SDP) is created with bipartisan support, providing dedicated federal funding for research and tribal health initiatives.
- 2016: The 21st Century Cures Act is signed into law, with significant input from caucus leadership, accelerating the development of medical products and innovations.
- 2022: The Inflation Reduction Act is passed, capping insulin costs for Medicare beneficiaries at $35 per month—a major victory for caucus members who had championed the issue for years.
- 2024: Representative Diana DeGette, a long-time caucus leader, loses her re-election bid, prompting a search for new Democratic leadership.
- 2026: Representative Kim Schrier is officially named the next Democratic co-chair.
- January 2027: Representative Schrier will formally assume her leadership role at the start of the 120th Congress.
Official Responses and Industry Reactions
The announcement of Representative Schrier’s new role has been met with widespread approval from the medical and advocacy communities. The Endocrine Society, a professional organization representing over 18,000 physicians and scientists, issued a statement praising the selection.
"The Society has a longstanding partnership with the Congressional Diabetes Caucus, and we work closely with the co-chairs on a wide range of issues impacting endocrinologists and the patients they treat living with diabetes," the organization stated. "We are grateful to Representative DeGette for her leadership and accomplishments on diabetes issues during her time in Congress. We look forward to working with Representative Schrier on these priorities in the next Congress and know she will make important contributions to legislation aimed at better prevention, increased research, and better treatment of diabetes."
Patient advocacy groups like JDRF have also noted the importance of having a leader who understands the daily mechanics of the disease. In legislative circles, Schrier is often seen as a bridge-builder, capable of explaining complex medical data to colleagues who may not have a scientific background. Her ability to translate clinical needs into legislative language is expected to be a primary asset for the caucus moving forward.
Broader Implications and Future Outlook
The transition to Schrier’s leadership comes at a time when the healthcare system is increasingly focused on the social determinants of health. Diabetes disproportionately affects minority communities and low-income populations, who often face barriers to healthy food, safe places to exercise, and affordable medical care. As a pediatrician, Schrier has frequently highlighted the rising rates of type 2 diabetes among children, a trend that health experts warn could lead to a massive public health crisis in the coming decades.
Observers suggest that Schrier may use her platform to push for more integrated school-based health programs and better nutritional standards in federal food assistance programs. By addressing diabetes at the pediatric level, her leadership could shift the caucus’s focus toward long-term prevention strategies alongside its traditional focus on research and treatment.
Furthermore, the bipartisan nature of the caucus remains its greatest strength. In a deeply polarized political environment, the shared goal of curing diabetes has remained one of the few areas where Republicans and Democrats consistently find common ground. With Representative Gus Bilirakis continuing his role, the caucus is well-positioned to maintain its influence in the House Energy and Commerce Committee and the Senate Health, Education, Labor, and Pensions (HELP) Committee.
As the 120th Congress approaches, the healthcare community will be watching closely to see how Representative Schrier’s personal experience and professional expertise shape the national conversation on diabetes. For the millions of Americans living with the condition, the hope is that this new leadership will lead to tangible improvements in care, lower costs, and eventually, a cure.
